PERIPHERALLY INSERTED CENTRAL CATHETER FOR LONG-TERM VASCULAR ACCESS IN PATIENTS WITH HEMORRHAGIC SYNDROME

The hemorrhagic syndrome is the relative contraindication for the central venous access. However, in the clinical practice, many patients with hemorrhagic syndrome need a long-term vascular access. Purpose of the study was to investigate the use of Peripherally Inserted Central Catheters (PICC) in patients with severe hemostatic disorders. Results. In total, 16 PICCs were implanted in 12 patients with hemorrhagic syndrome (6 hemophilia patients, 4 of them with inhibitor to FVIII, 1 patient with breast cancer and Willebrand disease, 3 patients with acute promyelocytic leukemia, 1 patient with multiple myeloma and 1 patient with myelodysplastic syndrome). Hemostasis was provided by recombinant activated factor VII (rFVlla), platelet and cryoprecipitate transfusions. The period of use of PICCs varied from 5 days to 1 year and 3 months. There were no thrombotic and infectious complications. PICC can be considered as a method of choice for long-term vascular access in patients with hemorrhagic syndrome.